Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M429Revenue $M50.2Net Margin (%)57.8Altman Z-Score3.7
Enterprise Value $M295EPS $0.6Operating Margin %57.5Piotroski F-Score5
P/E(ttm)16.6Beneish M-Score6.0Pre-tax Margin (%)57.8Higher ROA y-yY
Price/Book2.710-y EBITDA Growth Rate %--Quick Ratio4.9Cash flow > EarningsN
Price/Sales6.25-y EBITDA Growth Rate %--Current Ratio5.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)27.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)54.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VNDAJohn Paulson 2015-03-31 Add0.02%$8.99 - $14.58
($11.3)
$ 10.26-9%Add 8.97%3,950,000
VNDAJohn Paulson 2014-06-30 Add0.12%$9.7 - $16.96
($13.27)
$ 10.26-23%Add 129.80%3,200,000
VNDAJohn Paulson 2014-03-31 Buy 0.11%$10.5 - $18.71
($14.13)
$ 10.26-27%New holding1,392,500
VNDAFirst Eagle Investment 2013-09-30 Sold Out -0.02%$8.05 - $13.031
($10.72)
$ 10.26-4%Sold Out0
VNDAFirst Eagle Investment 2013-06-30 Reduce-0.01%$3.93 - $13
($6.73)
$ 10.2652%Reduce 48.99%975,000
VNDAFirst Eagle Investment 2012-12-31 Add0.01%$3.03 - $4.16
($3.54)
$ 10.26190%Add 43.16%1,911,452
VNDAFirst Eagle Investment 2010-03-31 Add0.04%$10.01 - $12.38
($10.94)
$ 10.26-6%Add 111.12%752,375
VNDAFirst Eagle Investment 2009-12-31 Buy 0.04%$9.59 - $11.84
($10.79)
$ 10.26-5%New holding356,375
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VNDA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Polymeropoulos Mihael HristosPresident and CEO 2015-03-10Sell21,900$10.53-8.07view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2015-03-10Sell12,450$10.53-8.07view
Baroldi PaoloSVP & Chief Medical Officer 2015-03-10Sell8,940$10.54-8.16view
DUGAN RICHARD WDirector 2015-03-09Sell4,804$10.69-9.45view
Flynn James E 2014-12-23Buy162,014$14.4-32.78view
Watkins ThomasDirector 2014-03-14Sell35,000$17.66-45.19view
Repella RobertSVP & Chief Commercial Officer 2013-11-21Sell107,500$12.03-19.53view
Polymeropoulos Mihael HristosPresident and CEO 2013-11-19Sell8,928$12.07-19.8view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2013-11-19Sell3,348$12.07-19.8view
Feeney John JosephSVP & Chief Medical Officer 2012-02-16Sell4,760$4.65108.17view

Press Releases about VNDA :

    Quarterly/Annual Reports about VNDA:

      News about VNDA:

      Articles On GuruFocus.com
      John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
      Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
      comment on VNDA Nov 12 2012 
      Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
      Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
      $VNDA New study started: Oct 15 2010 
      Hourly trend UP Aug 11 2010 
      Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
      upgraded to BUY Jul 07 2010 
      Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 

      More From Other Websites
      Vanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference May 11 2015
      Vanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference May 11 2015
      10-Q for Vanda Pharmaceuticals, Inc. May 09 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report May 07 2015
      4 Biotech Stocks Under $10 to Trade for Breakouts May 07 2015
      Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results May 06 2015
      Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today May 06 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 06 2015
      Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results May 06 2015
      American Foundation for the Blind Announces 2015 Helen Keller Achievement Award Honorees May 06 2015
      Q1 2015 Vanda Pharmaceuticals Inc Earnings Release - After Market Close May 06 2015
      10-K for Vanda Pharmaceuticals, Inc. May 05 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events May 05 2015
      Nasdaq stocks posting largest percentage decreases Apr 29 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 24 2015
      Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour... Apr 24 2015
      Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour... Apr 24 2015
      Vanda Pharmaceuticals Announces the Appointment of Chief Commercial Officer Apr 20 2015
      Vanda Pharmaceuticals Announces the Appointment of Chief Commercial Officer Apr 20 2015
      Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 Apr 16 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK